
Can altering RNA processing reach undruggable cancer targets? Remix Therapeutics CEO Peter Smith on the company’s experimental oral drugs that hit MYB, an elusive cancer target. thebioreport.podbean.com/e/m…

Principal, Levine Media Group, host of The Bio Report and RARECast podcasts, award-winning journalist focused on the life sciences.

Can altering RNA processing reach undruggable cancer targets? Remix Therapeutics CEO Peter Smith on the company’s experimental oral drugs that hit MYB, an elusive cancer target. thebioreport.podbean.com/e/m…

Carol Roberts @PBCers discusses her experience with the rare autoimmune condition primary biliary cholangitis, what a recent patient survey reveals about its day-to-day toll, and the evolving treatment landscape. @GlobalGenes #RARECast globalgenes.org/raredaily/th…

Nima Farzan @latigobio discusses the science behind the company’s approach to treating pain, what the data suggest about the potential to reduce opioid use after surgery, and what clinicians and insurers will need to see beyond regulatory approval. thebioreport.podbean.com/e/m…

Here's what you may have missed in October from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. linkedin.com/pulse/capitol-g…

Susan Busch @YearningNormal discusses her book Yearning for Normal, her son’s life with 22q11.2 deletion syndrome and the love and self-doubt of caregiving. @GlobalGenes #RARECast globalgenes.org/raredaily/ye…

Targeting metastatic breast cancer: @BriaCell CEO William Williams discusses its experimental, phase 3, off-the-shelf cell therapy. thebioreport.podbean.com/e/d…

Ankit Jain, CEO of Infinitus, discusses how his daughter’s rare disease exposed the obstacles families face, how the company’s AI agents work to reduce delays, and where human judgment and connection must remain central to care. @GlobalGenes #RARECast globalgenes.org/raredaily/us…

Arun Swaminathan @CoyaTx discusses how dysfunctional regulatory T cells contribute to neuroinflammation and neuronal damage in ALS, why the company is targeting them as a driver of disease progression, and the case for its dual immunomodulatory approach. globalgenes.org/raredaily/ta…

Geoff McDonough @RezeraInc discusses inflammation in heart disease, the company’s phase 3 trial of ruvonoflast in peripheral artery disease, and its next-generation, brain-penetrant NLRP3 inhibitor in development for neuroinflammatory conditions. thebioreport.podbean.com/e/t…

How can patient advocates and industry collaborate more effectively on drug development? Watch our panel from the @GlobalGenes Rare Drug Development Symposium @wendy_erler, Michelle Davis @ifopa, @TaiPasquini youtube.com/watch?v=B23GzMep…

Patient advocate Monica Dubeau of youmightbeazebra.com discusses fragmented care, diagnostic delay, and what must change for people with rare diseases. @GlobalGenes #RARECast globalgenes.org/raredaily/wh…

Here's what you may have missed in September from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. linkedin.com/feed/update/urn…

Ryan Beal @DyveBio discusses why acidity is an overlooked but foundational target in oncology, how its delivery technology may overcome the limitations of oral bicarbonate dosing, and indications beyond cancer that the company is pursuing. thebioreport.podbean.com/e/n…

Steven Ringel, founder and CEO of Nome, discusses helping families and patient groups evaluate genetic-medicine options, shape development plans, and connect with partners to advance individualized therapies toward the clinic. @globalgenes #RARECast globalgenes.org/raredaily/en…

Catharina Svanborg @HamletBioPharma , discusses Alpha1H—an experimental synthetic peptide inspired by a protein complex in human breast milk—designed to target bladder tumor cells while sparing healthy tissue. thebioreport.podbean.com/e/e…

Catharina Svanborg @HamletBioPharma , discusses Alpha1H—an experimental synthetic peptide inspired by a protein complex in human breast milk—designed to target bladder tumor cells while sparing healthy tissue. thebioreport.podbean.com/e/e…